查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1349437

藥物發現外包市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Drug Discovery Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 214 Pages | 商品交期: 2-10個工作天內

價格

藥物發現外包市場 - 報告範圍

TMR 關於全球藥物發現外包市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球藥物發現外包的收入2017-2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告也提供了2023年至2031年全球藥物發現外包市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解藥物發現外包市場。

市場概況
2023年市場價值 36 億美元
2031 年市場價值 75 億美元
年複合成長率 0.078%

該報告深入研究了全球藥物發現外包市場的競爭格局。全球藥物發現外包市場的主要參與者已經確定，並且每個參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球藥物發現外包市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 技術進步
  • 概述：綜合藥物發現 (IDD) 外包
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：按類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按類型，2017-2031
    • 化學服務
    • 生物服務
  • 市場吸引力分析：按類型

第 7 章：全球市場分析與預測：按藥物分子

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按藥物分子，2017-2031
    • 小分子
    • 大分子
  • 市場吸引力分析：按藥物分子

第 8 章：全球市場分析與預測：透過發現方法

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按發現方法，2017-2031
    • 經驗藥物發現
    • 合理的藥物發現
  • 市場吸引力分析：透過發現法

第 9 章：全球市場分析與預測：按治療領域

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依治療領域，2017-2031
    • 抗感染
    • 心血管
    • 中樞神經系統
    • 皮膚科
    • 內分泌
    • 胃腸道
    • 泌尿生殖系統
    • 免疫調節
    • 腫瘤學
    • 眼科
    • 呼吸系統
    • 其他
  • 市場吸引力分析：按治療領域

第 10 章：全球市場分析與預測：按工作流程

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依工作流程，2017-2031
    • 目標識別和篩選
    • 潛在客戶識別和候選最佳化
    • 疾病模型的開發
    • 製劑前研究
    • 整個臨床試驗
    • 其他
  • 市場吸引力分析：按工作流程

第 11 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按發現方法，2017-2031
    • 製藥公司
    • 生技公司
    • 學術機構
  • 市場吸引力分析：按最終用戶

第 12 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 13 章：北美市場分析與預測

第 14 章：歐洲市場分析與預測

第 15 章：亞太市場分析與預測

第 16 章：拉丁美洲市場分析與預測

第 17 章：中東和非洲市場分析與預測

第18章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Charles River Laboratories International, Inc.
    • WuXi AppTec Co., Ltd.
    • Albany Molecular Research Inc.
    • GVK Biosciences Private Limited
    • Sygnature Discovery
    • Pharmaron Beijing Co., Ltd.
    • Domainex Ltd.
    • Thermo Fisher Scientific, Inc.
    • Jubilant Biosys Ltd.
    • Evotec SE
    • Eurofins Discovery
    • GenScript Biotech Corporation
Product Code: TMRGL1841

Drug Discovery Outsourcing Market - Scope of Report

TMR's report on the global drug discovery outsourcing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug discovery outsourcing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug discovery outsourcing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug discovery outsourcing market.

Market Snapshot
Market Value in 2023US$ 3.6 Bn
Market Value in 2031US$ 7.5 Bn
CAGR7.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug discovery outsourcing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug discovery outsourcing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug discovery outsourcing market.

The report delves into the competitive landscape of the global drug discovery outsourcing market. Key players operating in the global drug discovery outsourcing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug discovery outsourcing market profiled in this report.

Key Questions Answered in Global Drug Discovery Outsourcing Market Report:

  • What is the sales/revenue generated by drug discovery outsourcing across all regions during the forecast period?
  • What are the opportunities in the global drug discovery outsourcing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Drug Discovery Outsourcing Market - Research Objectives and Research Approach

The comprehensive report on the global drug discovery outsourcing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug discovery outsourcing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug discovery outsourcing market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug Discovery Outsourcing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Drug Discovery Outsourcing Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Overview: Integrated Drug Discovery (IDD) outsourcing
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Chemistry Services
    • 6.3.2. Biology Services
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Drug Molecule

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 7.3.1. Small Molecules
    • 7.3.2. Large Molecules
  • 7.4. Market Attractiveness Analysis, by Drug Molecule

8. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Discovery Approach

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Discovery Approach, 2017-2031
    • 8.3.1. Empirical Drug Discovery
    • 8.3.2. Rational Drug Discovery
  • 8.4. Market Attractiveness Analysis, by Discovery Approach

9. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Therapeutic Area

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 9.3.1. Anti-infective
    • 9.3.2. Cardiovascular
    • 9.3.3. Central Nervous System
    • 9.3.4. Dermatology
    • 9.3.5. Endocrine
    • 9.3.6. Gastrointestinal
    • 9.3.7. Genitourinary System
    • 9.3.8. Immunomodulation
    • 9.3.9. Oncology
    • 9.3.10. Ophthalmology
    • 9.3.11. Respiratory System
    • 9.3.12. Others
  • 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Workflow

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Workflow, 2017-2031
    • 10.3.1. Target Identification and Screening
    • 10.3.2. Lead Identification and Candidate Optimization
    • 10.3.3. Development of Disease Models
    • 10.3.4. Pre-formulation Studies
    • 10.3.5. Entire Clinical Trials
    • 10.3.6. Others
  • 10.4. Market Attractiveness Analysis, by Workflow

11. Global Drug Discovery Outsourcing Market Analysis and Forecast, by End-user

  • 11.1. Introduction & Definition
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by Discovery Approach, 2017-2031
    • 11.3.1. Pharmaceutical Companies
    • 11.3.2. Biotechnology Companies
    • 11.3.3. Academic Institutes
  • 11.4. Market Attractiveness Analysis, by End-user

12. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2017-2031
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness Analysis, by Region

13. North America Drug Discovery Outsourcing Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Chemistry Services
    • 13.2.2. Biology Services
  • 13.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 13.3.1. Small Molecules
    • 13.3.2. Large Molecules
  • 13.4. Market Value Forecast, by Discovery Approach, 2017-2031
    • 13.4.1. Empirical Drug Discovery
    • 13.4.2. Rational Drug Discovery
  • 13.5. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 13.5.1. Anti-infective
    • 13.5.2. Cardiovascular
    • 13.5.3. Central Nervous System
    • 13.5.4. Dermatology
    • 13.5.5. Endocrine
    • 13.5.6. Gastrointestinal
    • 13.5.7. Genitourinary System
    • 13.5.8. Immunomodulation
    • 13.5.9. Oncology
    • 13.5.10. Ophthalmology
    • 13.5.11. Respiratory System
    • 13.5.12. Others
  • 13.6. Market Value Forecast, by Workflow, 2017-2031
    • 13.6.1. Target Identification and Screening
    • 13.6.2. Lead Identification and Candidate Optimization
    • 13.6.3. Development of Disease Models
    • 13.6.4. Pre-formulation Studies
    • 13.6.5. Entire Clinical Trials
    • 13.6.6. Others
  • 13.7. Market Value Forecast, by End-user, 2017-2031
    • 13.7.1. Pharmaceutical Companies
    • 13.7.2. Biotechnology Companies
    • 13.7.3. Academic Institutes
  • 13.8. Market Value Forecast, by Country, 2017-2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Type
    • 13.9.2. By Drug Molecule
    • 13.9.3. By Discovery Approach
    • 13.9.4. By Therapeutic Area
    • 13.9.5. By Workflow
    • 13.9.6. By End-user
    • 13.9.7. By Country

14. Europe Drug Discovery Outsourcing Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Chemistry Services
    • 14.2.2. Biology Services
  • 14.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 14.3.1. Small Molecules
    • 14.3.2. Large Molecules
  • 14.4. Market Value Forecast, by Discovery Approach, 2017-2031
    • 14.4.1. Empirical Drug Discovery
    • 14.4.2. Rational Drug Discovery
  • 14.5. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 14.5.1. Anti-infective
    • 14.5.2. Cardiovascular
    • 14.5.3. Central Nervous System
    • 14.5.4. Dermatology
    • 14.5.5. Endocrine
    • 14.5.6. Gastrointestinal
    • 14.5.7. Genitourinary System
    • 14.5.8. Immunomodulation
    • 14.5.9. Oncology
    • 14.5.10. Ophthalmology
    • 14.5.11. Respiratory System
    • 14.5.12. Others
  • 14.6. Market Value Forecast, by Workflow, 2017-2031
    • 14.6.1. Target Identification and Screening
    • 14.6.2. Lead Identification and Candidate Optimization
    • 14.6.3. Development of Disease Models
    • 14.6.4. Pre-formulation Studies
    • 14.6.5. Entire Clinical Trials
    • 14.6.6. Others
  • 14.7. Market Value Forecast, by End-user, 2017-2031
    • 14.7.1. Pharmaceutical Companies
    • 14.7.2. Biotechnology Companies
    • 14.7.3. Academic Institutes
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Italy
    • 14.8.5. Spain
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Type
    • 14.9.2. By Drug Molecule
    • 14.9.3. By Discovery Approach
    • 14.9.4. By Therapeutic Area
    • 14.9.5. By Workflow
    • 14.9.6. By End-user
    • 14.9.7. By Country/Sub-region

15. Asia Pacific Drug Discovery Outsourcing Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Type, 2017-2031
    • 15.2.1. Chemistry Services
    • 15.2.2. Biology Services
  • 15.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 15.3.1. Small Molecules
    • 15.3.2. Large Molecules
  • 15.4. Market Value Forecast, by Discovery Approach, 2017-2031
    • 15.4.1. Empirical Drug Discovery
    • 15.4.2. Rational Drug Discovery
  • 15.5. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 15.5.1. Anti-infective
    • 15.5.2. Cardiovascular
    • 15.5.3. Central Nervous System
    • 15.5.4. Dermatology
    • 15.5.5. Endocrine
    • 15.5.6. Gastrointestinal
    • 15.5.7. Genitourinary System
    • 15.5.8. Immunomodulation
    • 15.5.9. Oncology
    • 15.5.10. Ophthalmology
    • 15.5.11. Respiratory System
    • 15.5.12. Others
  • 15.6. Market Value Forecast, by Workflow, 2017-2031
    • 15.6.1. Target Identification and Screening
    • 15.6.2. Lead Identification and Candidate Optimization
    • 15.6.3. Development of Disease Models
    • 15.6.4. Pre-formulation Studies
    • 15.6.5. Entire Clinical Trials
    • 15.6.6. Others
  • 15.7. Market Value Forecast, by End-user, 2017-2031
    • 15.7.1. Pharmaceutical Companies
    • 15.7.2. Biotechnology Companies
    • 15.7.3. Academic Institutes
  • 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Type
    • 15.9.2. By Drug Molecule
    • 15.9.3. By Discovery Approach
    • 15.9.4. By Therapeutic Area
    • 15.9.5. By Workflow
    • 15.9.6. By End-user
    • 15.9.7. By Country/Sub-region

16. Latin America Drug Discovery Outsourcing Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Type, 2017-2031
    • 16.2.1. Chemistry Services
    • 16.2.2. Biology Services
  • 16.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 16.3.1. Small Molecules
    • 16.3.2. Large Molecules
  • 16.4. Market Value Forecast, by Discovery Approach, 2017-2031
    • 16.4.1. Empirical Drug Discovery
    • 16.4.2. Rational Drug Discovery
  • 16.5. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 16.5.1. Anti-infective
    • 16.5.2. Cardiovascular
    • 16.5.3. Central Nervous System
    • 16.5.4. Dermatology
    • 16.5.5. Endocrine
    • 16.5.6. Gastrointestinal
    • 16.5.7. Genitourinary System
    • 16.5.8. Immunomodulation
    • 16.5.9. Oncology
    • 16.5.10. Ophthalmology
    • 16.5.11. Respiratory System
    • 16.5.12. Others
  • 16.6. Market Value Forecast, by Workflow, 2017-2031
    • 16.6.1. Target Identification and Screening
    • 16.6.2. Lead Identification and Candidate Optimization
    • 16.6.3. Development of Disease Models
    • 16.6.4. Pre-formulation Studies
    • 16.6.5. Entire Clinical Trials
    • 16.6.6. Others
  • 16.7. Market Value Forecast, by End-user, 2017-2031
    • 16.7.1. Pharmaceutical Companies
    • 16.7.2. Biotechnology Companies
    • 16.7.3. Academic Institutes
  • 16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Type
    • 16.9.2. By Drug Molecule
    • 16.9.3. By Discovery Approach
    • 16.9.4. By Therapeutic Area
    • 16.9.5. By Workflow
    • 16.9.6. By End-user
    • 16.9.7. By Country/Sub-region

17. Middle East & Africa Drug Discovery Outsourcing Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Type, 2017-2031
    • 17.2.1. Chemistry Services
    • 17.2.2. Biology Services
  • 17.3. Market Value Forecast, by Drug Molecule, 2017-2031
    • 17.3.1. Small Molecules
    • 17.3.2. Large Molecules
  • 17.4. Market Value Forecast, by Discovery Approach, 2017-2031
    • 17.4.1. Empirical Drug Discovery
    • 17.4.2. Rational Drug Discovery
  • 17.5. Market Value Forecast, by Therapeutic Area, 2017-2031
    • 17.5.1. Anti-infective
    • 17.5.2. Cardiovascular
    • 17.5.3. Central Nervous System
    • 17.5.4. Dermatology
    • 17.5.5. Endocrine
    • 17.5.6. Gastrointestinal
    • 17.5.7. Genitourinary System
    • 17.5.8. Immunomodulation
    • 17.5.9. Oncology
    • 17.5.10. Ophthalmology
    • 17.5.11. Respiratory System
    • 17.5.12. Others
  • 17.6. Market Value Forecast, by Workflow, 2017-2031
    • 17.6.1. Target Identification and Screening
    • 17.6.2. Lead Identification and Candidate Optimization
    • 17.6.3. Development of Disease Models
    • 17.6.4. Pre-formulation Studies
    • 17.6.5. Entire Clinical Trials
    • 17.6.6. Others
  • 17.7. Market Value Forecast, by End-user, 2017-2031
    • 17.7.1. Pharmaceutical Companies
    • 17.7.2. Biotechnology Companies
    • 17.7.3. Academic Institutes
  • 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of MEA
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Type
    • 17.9.2. By Drug Molecule
    • 17.9.3. By Discovery Approach
    • 17.9.4. By Therapeutic Area
    • 17.9.5. By Workflow
    • 17.9.6. By End-user
    • 17.9.7. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 18.2. Market Share Analysis, by Company (2022)
  • 18.3. Company Profiles
    • 18.3.1. Charles River Laboratories International, Inc.
      • 18.3.1.1. Company Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. SWOT Analysis
      • 18.3.1.4. Financial Overview
      • 18.3.1.5. Strategic Overview
    • 18.3.2. WuXi AppTec Co., Ltd.
      • 18.3.2.1. Company Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. SWOT Analysis
      • 18.3.2.4. Financial Overview
      • 18.3.2.5. Strategic Overview
    • 18.3.3. Albany Molecular Research Inc.
      • 18.3.3.1. Company Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. SWOT Analysis
      • 18.3.3.4. Financial Overview
      • 18.3.3.5. Strategic Overview
    • 18.3.4. GVK Biosciences Private Limited
      • 18.3.4.1. Company Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. SWOT Analysis
      • 18.3.4.4. Financial Overview
      • 18.3.4.5. Strategic Overview
    • 18.3.5. Sygnature Discovery
      • 18.3.5.1. Company Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. SWOT Analysis
      • 18.3.5.4. Financial Overview
      • 18.3.5.5. Strategic Overview
    • 18.3.6. Pharmaron Beijing Co., Ltd.
      • 18.3.6.1. Company Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. SWOT Analysis
      • 18.3.6.4. Financial Overview
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Domainex Ltd.
      • 18.3.7.1. Company Overview
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. SWOT Analysis
      • 18.3.7.4. Financial Overview
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Thermo Fisher Scientific, Inc.
      • 18.3.8.1. Company Overview
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. SWOT Analysis
      • 18.3.8.4. Financial Overview
      • 18.3.8.5. Strategic Overview
    • 18.3.9. Jubilant Biosys Ltd.
      • 18.3.9.1. Company Overview
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. SWOT Analysis
      • 18.3.9.4. Financial Overview
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Evotec SE
      • 18.3.10.1. Company Overview
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. SWOT Analysis
      • 18.3.10.4. Financial Overview
      • 18.3.10.5. Strategic Overview
    • 18.3.11. Eurofins Discovery
      • 18.3.11.1. Company Overview
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. SWOT Analysis
      • 18.3.11.4. Financial Overview
      • 18.3.11.5. Strategic Overview
    • 18.3.12. GenScript Biotech Corporation
      • 18.3.12.1. Company Overview
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. SWOT Analysis
      • 18.3.12.4. Financial Overview
      • 18.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 02: Global Drug Discovery Outsourcing Market Value (`) Forecast, by Drug Molecule, 2017-2031
  • Table 03: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 04: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 05: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 06: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 07: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Region, 2017-2031
  • Table 08: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 09: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
  • Table 10: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 11: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 12: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 13: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 14: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 15: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 16: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
  • Table 17: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 18: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 19: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 20: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 21: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 23: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
  • Table 24: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 25: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 26: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 27: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 28: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 29: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 30: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
  • Table 31: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 32: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 33: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 34: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 35: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 36: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
  • Table 37: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
  • Table 38: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
  • Table 39: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
  • Table 40: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 41: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
  • Table 42: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 02: Global Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 03: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 04: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Target Identification and Screening, 2017-2031
  • Figure 05: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Lead Identification and Candidate Optimization, 2017-2031
  • Figure 06: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Development of Disease Models, 2017-2031
  • Figure 07: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pre-formulation Studies, 2017-2031
  • Figure 08: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Entire Clinical Trials, 2017-2031
  • Figure 09: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031
  • Figure 10: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 11: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 12: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Small Molecules, 2017-2031
  • Figure 13: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Large Molecules, 2017-2031
  • Figure 14: Global Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 15: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Empirical Drug Discovery, 2017-2031
  • Figure 16: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Rational Drug Discovery, 2017-2031
  • Figure 17: Global Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 18: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Anti-infective, 2017-2031
  • Figure 19: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Cardiovascular, 2017-2031
  • Figure 20: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Central Nervous System, 2017-2031
  • Figure 21: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Dermatology, 2017-2031
  • Figure 22: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Endocrine, 2017-2031
  • Figure 23: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Gastrointestinal, 2017-2031
  • Figure 24: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Genitourinary System, 2017-2031
  • Figure 25: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Immunomodulation, 2017-2031
  • Figure 26: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Oncology, 2017-2031
  • Figure 27: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Ophthalmology, 2017-2031
  • Figure 28: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Respiratory System, 2017-2031
  • Figure 29: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031
  • Figure 30: Global Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 31: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 32: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Chemistry Services, 2017-2031
  • Figure 33: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biology Services, 2017-2031
  • Figure 34: Global Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 35: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 36: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pharmaceutical Companies, 2017-2031
  • Figure 37: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biotechnology Companies, 2017-2031
  • Figure 38: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Academic Institutes, 2017-2031
  • Figure 39: Global Drug Discovery Outsourcing Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 40: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 41: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 42: North America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 43: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 44: North America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 45: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
  • Figure 46: North America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 47: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
  • Figure 48: North America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 49: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 50: North America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 51: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 52: North America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 53: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 54: North America Drug Discovery Outsourcing Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 55: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 56: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 57: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 58: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 59: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 60: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
  • Figure 61: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 62: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
  • Figure 63: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 64: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 65: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 66: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 67: Europe Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 68: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 69: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 70: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 71: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 72: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 73: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 74: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 75: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
  • Figure 76: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 77: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
  • Figure 78: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 79: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 80: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 81: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 82: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 83: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 84: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 85: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 86: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 87: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 88: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 89: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 90: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
  • Figure 91: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 92: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
  • Figure 93: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 94: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 95: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 96: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 97: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 98: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 99: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 100: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 101: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 102: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
  • Figure 103: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
  • Figure 104: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
  • Figure 105: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
  • Figure 106: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
  • Figure 107: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
  • Figure 108: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 109: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
  • Figure 110: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 111: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 112: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 113: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 114: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 115: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031